Compare Abeona Therapeutics Inc (ABEO) vs Barrick Gold Corp (B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Barrick Gold Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Barrick Gold Corp trades at $35.48 (market cap $61.76B). The key difference: Barrick Gold Corp is far larger — about 165.4× Abeona Therapeutics Inc's market cap, and Barrick Gold Corp pays a 1.9% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | B | |
|---|---|---|
Market Cap | $373.32M | $61.76B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $52.97 |
52-Week Low | $4.17 | $20.73 |
Enterprise Value | $228.22M | $59.35B |
Dividend Yield | — | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Barrick Mining (B) trades at $36.86, down 3.55% over 24 hours, with technical indicators signaling a bearish trend. The company demonstrates strong fundamentals with a P/E of 10.07, net income margin of 32.14%, and consistent earnings beats in recent quarters. Revenue surged to $17.0B in 2025, up from $12.9B in 2024, while cash flow from operations improved to $7.7B. A dividend of $0.18 per share is scheduled for payment on June 15, 2026.
The stock presents a value opportunity with a consensus price target of $51.33, implying 39% upside, supported by 68% analyst buy ratings. Risks include gold price volatility and operational execution challenges. Strong cash flow generation and low debt levels provide a solid foundation for growth, though near-term technical weakness may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →
